DocDollars

Madrigal Pharmaceuticals

PA · United States · Reporting entity ID 100001448154

Total reported 2019–2025
$57.9M
#152 of 2,960 reporting companies — 0.1% of all reported industry payments
$20.1M in general payments across 95,810 records, plus $37.8M in research funding across 5,787 records.

How it breaks down

General payments $20,088,730
Research funding $37,771,098

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Madrigal Pharmaceuticals reported $57.9M to US doctors and teaching hospitals from 2019 to 2025, ranking #152 of 2,960 reporting companies. 65% of that was research funding and 35% general payments such as consulting, speaking, food and travel. 95,810 general payment records and 5,787 research records were filed.

Common questions about Madrigal Pharmaceuticals

How much has Madrigal Pharmaceuticals paid US doctors?

Madrigal Pharmaceuticals reported $57,859,829 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $20,088,730 in general payments, $37,771,098 in research funding.

How does Madrigal Pharmaceuticals rank among drug and device companies?

It ranks #152 of 2,960 reporting entities by total reported value, about 0.1% of all industry payments in the dataset.

Does a payment from Madrigal Pharmaceuticals mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.